ClinicalTrials.gg
CompletedNCT05373355Updated Mar 1, 2024

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

A Phase 1 interventional study of TLL018 tablets in Chronic Spontaneous Urticaria, sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Enrollment
26th of 30
41 · median 110
Started
2022
with 2 others
Phase 1
7 of 34
3 open now
Registered
6th of 34
by date
Lead sponsor
3 of 34
Hangzhou Highlightll Pharmaceutical Co., Ltd

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 26th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 1, and was the 6th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.

Read the detailed description

Successfully screened subjects will be randomized in a ratio of 1:1:1. After a 4-week screening period (day -28-0), subjects will be randomly assigned to treatment for 12 weeks.

Clinical Urticaria Activity Score (UAS), dermatological Quality of Life Index (DLQI), physical exams and Laboratory tests will be performed at baseline, the end of weeks 4, 8 and 12 respectively.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had a diagnosis of moderate to severe Chronic Spontaneous Urticaria for at least 6 months prior to Baseline;
  • Subjects with moderate to severe Chronic Spontaneous Urticaria UAS7 score ≥16 at Baseline;
  • Able and willing to give written .

Exclusion criteria

Exclusion Criteria:

  • Other types of Chronic Urticaria (such as Artificial urticaria, cold-contact urticaria, heat-contact urticaria etc);
  • Other disease with symptoms of urticaria or angioedema, e.g., Urticaria vasculitis, color Vegetarian urticaria, erythema multiforme;
  • History or symptoms of in any organ system regardless of treatment, and regardless of evidence of recurrence or ;
  • Any uncontrolled laboratory abnormality that would affect interpretation of study data or the subject's participation in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Cohort 1

    TLL018 tablets 1piece,BID

    Drug: TLL018 tablets

  • Experimental
    Cohort 2

    TLL018 tablets 3pieces, BID

    Drug: TLL018 tablets

  • Placebo comparator
    Cohort 3

    TLL018 placeboes 3pieces, BID

    Drug: TLL018 tablets

Interventions

  • Oral tablets administered at different doses BID daily for 12 weeks.

    Also known as: TLL018 Placeboes

06

What researchers measure

Primary outcomes

  1. treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Time frame: From day 1 to Weeks 4

  2. adverse events (AEs) according to severity

    Number of adverse events (AEs) according to severity

    Time frame: From day 1 to Weeks 4

  3. blood pressure from baseline

    Change of blood pressure from baseline

    Time frame: From day 1 to Weeks 4

  4. pulse rate from baseline

    Change of pulse rate from baseline

    Time frame: From day 1 to Weeks 4

  5. respiratory rate from baseline

    Change of respiratory rate from baseline

    Time frame: From day 1 to Weeks 4

  6. temperature from baseline

    Change of oral temperature from baseline

    Time frame: From day 1 to Weeks 4

  7. clinical laboratory abnormalities compared to baseline

    Number of participants with clinical laboratory abnormalities compared to baseline

    Time frame: From day 1 to Weeks 4

  8. ECG parameters from baseline

    Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline

    Time frame: From day 1 to Weeks 4

  9. physical examination findings from baseline

    Number of participants with changes in physical examination findings from baseline

    Time frame: From day 1 to Weeks 4

  10. Cmax of TLL018

    Maximum observed plasma concentration (Cmax) of TLL018

    Time frame: 0 hour (pre-dose - within 30 minutes prior to dosing), and at 0.5, 1, 2, 4 and 8 hours post-dose

Secondary outcomes

  1. treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Time frame: From week 4 to Weeks 12

  2. adverse events (AEs) according to severity

    Number of adverse events (AEs) according to severity

    Time frame: From week 4 to Weeks 12

  3. blood pressure from baseline

    Change of blood pressure from baseline

    Time frame: From week 4 to Weeks 12

  4. pulse rate from baseline

    Change of pulse rate from baseline

    Time frame: From week 4 to Weeks 12

  5. respiratory rate from baseline

    Change of respiratory rate from baseline

    Time frame: From week 4 to Weeks 12

  6. temperature from baseline

    Change of oral temperature from baseline

    Time frame: From week 4 to Weeks 12

  7. clinical laboratory abnormalities compared to baseline

    Number of participants with clinical laboratory abnormalities compared to baseline

    Time frame: From week 4 to Weeks 12

  8. ECG parameters from baseline

    Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline

    Time frame: From week 4 to Weeks 12

  9. physical examination findings from baseline

    Number of participants with changes in physical examination findings from baseline

    Time frame: From week 4 to Weeks 12

  10. UAS7 score decreased from baseline at week 4

    Change in mean value of UAS7 score from baseline at week 4 when comparing TLL-018 with placebo

    Time frame: Baseline to Week 4

  11. UAS7 score decreased from baseline at week 8

    Change in mean value of UAS7 score from baseline at week 8 when comparing TLL-018 with placebo

    Time frame: Time Frame: Baseline to Week 8

  12. UAS7 score decreased from baseline at week 12

    Change in mean value of UAS7 score from baseline at week 12 when comparing TLL-018 with placebo

    Time frame: Baseline to Week 12

  13. DLQI score decreased from baseline at week 4

    Change in mean value of DLQI score from baseline at week 4 when comparing TLL-018 with placebo

    Time frame: Baseline to Weeks 4

  14. DLQI score decreased from baseline at week 8

    Change in mean value of DLQI score from baseline at week 8 when comparing TLL-018 with placebo

    Time frame: Baseline to Weeks 8

  15. DLQI score decreased from baseline at week 12

    Change in mean value of DLQI score from baseline at week 12 when comparing TLL-018 with placebo

    Time frame: Baseline to Weeks 12

07

Study locations

1 site
  • Hospital For Skin Diseases,Institute of Dermatology Chinese Academy of Medical Sciences, Peking Union Medical College
    Nanjing, Jiangsu 210042, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Sep 2023, 15 months.

Of 15 phase 1 interventional studies under Chronic Urticaria, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 15 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 13, 2022
StartActual
May 10, 2022
Primary completionActual
Sep 7, 2023
CompletionActual
Sep 7, 2023
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05373355
Responsible party
Sponsor
First posted
May 13, 2022
Start date
May 10, 2022
Primary completion
Sep 7, 2023
Completion
Sep 7, 2023
Last update
Mar 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLL-018

Start the discussion